Zacks Investment Research upgraded shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) from a sell rating to a hold rating in a report issued on Wednesday morning.

According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “

A number of other analysts have also weighed in on KPTI. Canaccord Genuity restated a buy rating and set a $20.00 target price on shares of Karyopharm Therapeutics in a report on Monday, March 13th. Wedbush restated an outperform rating and set a $14.00 target price on shares of Karyopharm Therapeutics in a report on Saturday, March 4th. Jefferies Group LLC restated a buy rating and set a $14.00 target price on shares of Karyopharm Therapeutics in a report on Monday, March 13th. Finally, HC Wainwright restated a buy rating and set a $14.00 target price (down previously from $15.00) on shares of Karyopharm Therapeutics in a report on Tuesday, March 7th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $13.76.

Karyopharm Therapeutics (NASDAQ:KPTI) opened at 10.37 on Wednesday. The stock has a 50 day moving average price of $10.71 and a 200-day moving average price of $9.69. The stock’s market capitalization is $427.69 million. Karyopharm Therapeutics has a 1-year low of $6.27 and a 1-year high of $14.63.

Your IP Address:

Several institutional investors have recently modified their holdings of KPTI. Endurance Wealth Management Inc. increased its position in shares of Karyopharm Therapeutics by 166.7% in the third quarter. Endurance Wealth Management Inc. now owns 16,000 shares of the company’s stock worth $156,000 after buying an additional 10,000 shares during the last quarter. Bank of Montreal Can acquired a new position in shares of Karyopharm Therapeutics during the third quarter worth about $159,000. Metropolitan Life Insurance Co. NY increased its position in shares of Karyopharm Therapeutics by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 21,911 shares of the company’s stock worth $206,000 after buying an additional 2,460 shares during the last quarter. Trexquant Investment LP acquired a new position in shares of Karyopharm Therapeutics during the fourth quarter worth about $273,000. Finally, Citadel Advisors LLC acquired a new position in shares of Karyopharm Therapeutics during the third quarter worth about $286,000. 56.97% of the stock is currently owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

5 Day Chart for NASDAQ:KPTI

Get a free copy of the Zacks research report on Karyopharm Therapeutics (KPTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Karyopharm Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.